Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers.
By A. Imhof, P. Brunner, Nicolas Marincek, M. Briel, C. Schindler, H. Rasch, H. Mäcke, C. Rochlitz, J. Müller-Brand, M. Walter. Journal of Clinical Oncology, 2011
622 citations recorded by the source corpus.
Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Oncology
View Paper: https://www.semanticscholar.org/paper/3dc57f620dd92e58779a7f8722daf3b71dac3cbe
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- L. Bodei
- T. M. O’Dorisiol
- J. Mueller‐Brand
- Marianne Pavel
- J. Howe
- R. Baum
- Dieter Hörsch
- M. Cremonesi
Citations in the corpus
- Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. (2015, neutral): “2%) [153].”
- The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours (2013, background): “Survival analyses have shown that patients with high sstr tumour expression at study entry, treated with either (177)LuDOTATATE or (90)Y-DOTATOC, show significantly higher objective responses that translate into significantly longer survival [48, 50].”